Ser53
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser53  -  MCM2 (human)

Site Information
LPPFEDEsEGLLGtE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 473058

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 3 , 4 ) , immunoprecipitation ( 3 , 4 ) , mass spectrometry ( 6 , 9 , 10 , 11 , 12 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 26 , 28 , 30 , 31 , 32 , 35 ) , mutation of modification site ( 27 ) , phospho-antibody ( 2 , 3 , 4 , 5 , 7 , 13 , 25 , 27 , 33 , 35 ) , western blotting ( 2 , 3 , 4 , 5 , 7 , 8 , 13 , 25 , 27 , 35 )
Disease tissue studied:
bone cancer ( 8 , 13 ) , breast cancer ( 7 ) , breast ductal carcinoma ( 7 ) , colorectal cancer ( 7 ) , colorectal carcinoma ( 7 ) , gastric cancer ( 11 ) , leukemia ( 30 ) , chronic myelogenous leukemia ( 30 ) , non-small cell lung cancer ( 9 , 10 , 12 ) , non-small cell lung adenocarcinoma ( 10 ) , lymphoma ( 6 ) , Burkitt's lymphoma ( 6 ) , follicular lymphoma ( 6 ) , mantle cell lymphoma ( 6 ) , pancreatic cancer ( 4 ) , pancreatic carcinoma ( 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
CDC7 (human) ( 8 ) , LEDGF (human) ( 25 ) , PRIMPOL (human) ( 2 )
Putative in vivo kinases:
CDC7 (human) ( 2 , 3 , 4 , 8 , 25 , 33 , 35 )
Kinases, in vitro:
CDC7 (human) ( 25 , 29 ) , CDK2 (human) ( 35 ) , CDK7 (human) ( 34 , 35 ) , CK2A1 (human) ( 35 )
Treatments:
etoposide ( 33 ) , HU-210 ( 33 ) , hydroxyurea ( 8 ) , PHA-767491 ( 2 , 3 , 4 , 5 , 7 , 8 ) , PKR_inhibitor ( 7 ) , serum ( 35 ) , serum_starvation ( 35 ) , siRNA ( 33 ) , tautomycin ( 3 ) , thymidine ( 35 ) , XL413 ( 7 )

Downstream Regulation
Effects of modification on MCM2:
enzymatic activity, induced ( 5 ) , molecular association, regulation ( 35 )
Effects of modification on biological processes:
apoptosis, inhibited ( 4 , 7 ) , cell cycle regulation ( 3 ) , cell growth, altered ( 33 ) , chromatin organization, altered ( 35 )
Induce interaction with:
DNA ( 35 )

References 

1

Wang C, et al. (2019) Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 574, 268-272
31578521   Curated Info

2

Rodriguez-Acebes S, Mourón S, Méndez J (2018) Uncoupling fork speed and origin activity to identify the primary cause of replicative stress phenotypes. J Biol Chem
29959228   Curated Info

3

Alver RC, Chadha GS, Gillespie PJ, Blow JJ (2017) Reversal of DDK-Mediated MCM Phosphorylation by Rif1-PP1 Regulates Replication Initiation and Replisome Stability Independently of ATR/Chk1. Cell Rep 18, 2508-2520
28273463   Curated Info

4

Huggett MT, et al. (2016) Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint. Oncotarget 7, 18495-507
26921250   Curated Info

5

Chen YH, et al. (2015) ATR-Mediated Phosphorylation of FANCI Regulates Dormant Origin Firing in Response to Replication Stress. Mol Cell 58, 323-38
25843623   Curated Info

6

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

7

Sasi NK, et al. (2014) The Potent Cdc7-Dbf4 (DDK) Kinase Inhibitor XL413 Has Limited Activity in Many Cancer Cell Lines and Discovery of Potential New DDK Inhibitor Scaffolds. PLoS One 9, e113300
25412417   Curated Info

8

Yamada M, et al. (2013) ATR-Chk1-APC/CCdh1-dependent stabilization of Cdc7-ASK (Dbf4) kinase is required for DNA lesion bypass under replication stress. Genes Dev 27, 2459-72
24240236   Curated Info

9

Rikova K (2013) CST Curation Set: 18459; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

10

Rikova K (2013) CST Curation Set: 18458; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

11

Rikova K (2012) CST Curation Set: 16141; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

12

Rikova K (2012) CST Curation Set: 16142; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

13

Martin L, Rainey M, Santocanale C, Gardner LB (2012) Hypoxic activation of ATR and the suppression of the initiation of DNA replication through cdc6 degradation. Oncogene 31, 4076-84
22179839   Curated Info

14

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

15

Mulhern D (2012) CST Curation Set: 13761; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

16

Mulhern D (2011) CST Curation Set: 12710; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

17

Mulhern D (2011) CST Curation Set: 12712; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

18

Guo A (2011) CST Curation Set: 11983; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

19

Guo A (2011) CST Curation Set: 11985; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

20

Guo A (2011) CST Curation Set: 11986; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

21

Guo A (2011) CST Curation Set: 11987; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

22

Guo A (2011) CST Curation Set: 11988; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

23

Guo A (2011) CST Curation Set: 11989; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif Antibody Cat#: 9601
Curated Info

24

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

25

Hughes S, et al. (2010) Transcriptional co-activator LEDGF interacts with Cdc7-activator of S-phase kinase (ASK) and stimulates its enzymatic activity. J Biol Chem 285, 541-54
19864417   Curated Info

26

Guo A (2009) CST Curation Set: 8004; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

27

Chuang LC, et al. (2009) Phosphorylation of Mcm2 by Cdc7 promotes pre-replication complex assembly during cell-cycle re-entry. Mol Cell 35, 206-16
19647517   Curated Info

28

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

29

Charych DH, et al. (2008) Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites on MCM2 in cancer cells. J Cell Biochem 104, 1075-86
18286467   Curated Info

30

Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

31

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

32

Stokes M (2008) CST Curation Set: 3885; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

33

Tenca P, et al. (2007) Cdc7 is an active kinase in human cancer cells undergoing replication stress. J Biol Chem 282, 208-15
17062569   Curated Info

34

Cho WH, et al. (2006) CDC7 kinase phosphorylates serine residues adjacent to acidic amino acids in the minichromosome maintenance 2 protein. Proc Natl Acad Sci U S A 103, 11521-6
16864800   Curated Info

35

Montagnoli A, et al. (2006) Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases. J Biol Chem 281, 10281-90
16446360   Curated Info